Literature DB >> 20140794

A qualitative study of participant adherence in a randomized controlled trial of herpes suppressive therapy for HIV prevention in Tanzania.

Mary L Plummer1, Deborah Watson-Jones, Shelley Lees, Kathy Baisley, Salma Matari, John Changalucha, Tim Clayton, Kokugonza Mugeye, Clare Tanton, Helen A Weiss, David A Ross, Richard J Hayes.   

Abstract

Poor participant adherence to treatment may contribute to lack of impact in some biomedical HIV prevention trials. This qualitative study explored adherence in a randomized controlled trial of herpes suppressive therapy to reduce HIV acquisition and infectivity among 1305 Tanzanian women. The trial found participants completed 72% of visits on treatment; 52-56% of women on treatment had > or = 90% adherence by pill count estimate; and between six and nine months 30/86 (35%) of urine samples from acyclovir recipients tested acyclovir negative, and 7/86 (8%) from placebo recipients tested acyclovir positive. Twenty in-depth interviews (IDIs) were conducted after 30 months with respondents randomly selected from "acyclovir negative" acyclovir recipients and "acyclovir positive" placebo recipients, or by preliminary pill count adherence categories ("under users," "good users," and "over users"). Almost all respondents reported appropriate adherence and positive trial attitudes, e.g., trusting staff, appreciating services, perceiving pills as beneficial. Fourteen understood placebo use, and six understood the trial purpose. Notably, 5/9 acyclovir recipients and 1/11 placebo recipients believed their pills had treated pre-existing sexually transmitted infections. Limited understanding did not negatively affect reported adherence. Reported adherence problems usually related to illness, travel, and/or family obligations (e.g., husband's disapproval). "Acyclovir positive" placebo recipients denied taking other participants' pills. The IDIs also did not resolve discrepant reports of pill loss or theft. Biomedical HIV interventions often have strong behavioral components that require close attention during intervention development, trial design, and process and impact evaluation. This study identified topics which warrant further consideration, including: information reinforcement and comprehension assessment throughout a trial for long-term participant understanding; involving partners in adherence promotion activities; strategizing with participants to maintain adherence during familial illnesses or other crises; and close monitoring, identification, and follow-up of (1) individuals with discrepant biological tests, and (2) other sources of the treatment in the trial area. Methodological research is also needed to improve adherence measures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140794     DOI: 10.1080/09540120903202889

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  7 in total

Review 1.  Neuropsychiatric complications of aging with HIV.

Authors:  Crystal C Watkins; Glenn J Treisman
Journal:  J Neurovirol       Date:  2012-05-30       Impact factor: 2.643

Review 2.  Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.

Authors:  Crystal C Watkins; Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

3.  Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.

Authors:  Alexandra M Minnis; Ariane van der Straten; Parichat Salee; Craig W Hendrix
Journal:  AIDS Behav       Date:  2016-07

4.  A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial.

Authors:  Shevin T Jacob; Jared M Baeten; James P Hughes; Jesús Peinado; Jing Wang; Jorge Sanchez; Stewart E Reid; Sinead Delany-Moretlwe; Frances Cowan; Jonathan D Fuchs; Beryl Koblin; Sam Griffith; Anna Wald; Connie Celum
Journal:  AIDS Behav       Date:  2011-07

5.  Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.

Authors:  Gaudensia Mutua; Eduard Sanders; Peter Mugo; Omu Anzala; Jessica E Haberer; David Bangsberg; Burc Barin; James F Rooney; David Mark; Paramesh Chetty; Patricia Fast; Frances H Priddy
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

6.  NIMH Project Accept (HPTN 043): results from in-depth interviews with a longitudinal cohort of community members.

Authors:  Suzanne Maman; Heidi van Rooyen; Petra Stankard; Alfred Chingono; Tshifhiwa Muravha; Jacob Ntogwisangu; Zipho Phakathi; Namtip Srirak; Stephen F Morin
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

7.  The impact of HIV/AIDS on compliance with antidepressant treatment in major depressive disorder: A prospective study in a South African private healthcare cohort.

Authors:  Francois N Slabbert; Brian H Harvey; Christiaan B Brink; Martie S Lubbe
Journal:  AIDS Res Ther       Date:  2015-04-14       Impact factor: 2.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.